Piper Sandler Rates Twist Bioscience (TWST) buy, $85 Price Target
Analyst David Westenberg keeps a Buy rating on Twist Bioscience, targeting $85 as the stock trades at $80.79, a 5.21% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Piper Sandler rated Twist Bioscience Corporation ($TWST) "buy" with a $85 price target on June 11, 2026.
Since the rating, $TWST is up 18.2% after 1 week, up 22.0% after 1 month and up 79.3% to date (from the $74.05 close on Jun 11, 2026).
TWST
Twist Bioscience Corporation
Key Points
- Piper Sandler reiterated its Buy rating on Twist Bioscience, setting a target price of $85, while the stock is currently at $80.79.
- Piper Sandler's $85 price target implies 5.21% upside from Twist Bioscience Corporation's ($TWST) current $80.79 share price.
- Twist Bioscience has a market cap of about $10.99 billion and is in the biotechnology sector, focused on synthetic DNA products.
- Twelve analysts currently cover Twist Bioscience, with a consensus recommendation to Buy and a mean price target of $109.58.
Get $TWST trade alerts by text
We text you when insiders, Congress or big funds trade $TWST. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Twist Bioscience Corporation alert may contain errors. Disclosures
Piper Sandler's Continued Confidence in Twist Bioscience
Piper Sandler reiterated its Buy rating for Twist Bioscience Corporation (TWST) on June 11, 2026, maintaining a target price of $85. The stock closed at $80.79 on the NasdaqGS, indicating a strong outlook from the analyst firm.
Analysts Set New Price Targets
David Westenberg of Piper Sandler emphasized the ongoing positive sentiment towards Twist Bioscience. The company, which specializes in synthetic DNA-based products for various applications, continues to attract analyst interest. Other firms have also maintained positive ratings with high price targets. On October 13, TD Cowen maintained a Buy rating with a target of $190, and Canaccord Genuity also kept its Buy rating with a target of $205 on October 12. This reflects a bullish consensus among analysts, with a mean price target of approximately $109.58 from twelve total opinions.
Stock Context
Twist Bioscience shares have seen a significant fluctuation over the past year, with a 52-week low of $23.30 and a high of $170.23. Currently trading around $80.79, the stock is below its 50-day moving average of $119.81, which might attract some buyers looking for a potential rebound.
$TWST price target
Twist Bioscience Corporation daily closes and this analyst's $85 target. Not advice.
Recent Earnings
For the year ended December 31, 2025, Twist Bioscience reported revenue of approximately $431.8 million, reflecting a growth rate of 23.2%. However, the company posted a negative earnings per share (EPS) of -$2.24, with a net margin of -31.66%. Its next earnings report is scheduled for November 16, 2026, giving investors a chance to reassess its financial health.
What Twist Bioscience Corporation Does
Twist Bioscience Corporation, headquartered in South San Francisco, California, creates synthetic DNA products for various industries, including healthcare and biotechnology. Its products are crucial for development in therapeutics and diagnostics, making the analyst ratings significant as they reflect investor confidence in the company's growth potential.
What to Watch at Twist Bioscience Corporation
Investors should keep an eye on the upcoming earnings report on November 16, 2026, which will provide further insights into Twist Bioscience's performance. Additionally, the repeated positive ratings from analysts suggest a continuing interest in the company as it navigates the competitive biotechnology landscape.
Related Filing Alerts
Source: Piper Sandler's rating change on $TWST (Jun 11, 2026). Written by software, not financial advice. How we make alerts